Immunovant, Inc.

IMVT · NASDAQ
Analyze with AI
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Operating Activities
Net Income-$414-$259-$211-$157
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$49$41$32$34
Change in WC-$12$3-$11$15
Other Non-Cash$0$1$1$1
Operating Cash Flow-$376-$214-$188-$106
Investing Activities
PP&E Inv.-$1-$0-$0-$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$1-$0-$0-$0
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$450$473$71$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$4-$0$0$200
Financing Cash Flow$454$472$71$200
Forex Effect$1$1$0-$0
Net Chg. in Cash$79$259-$117$94
Supplemental Information
Beg. Cash$635$377$494$400
End Cash$714$635$377$494
Free Cash Flow-$377-$215-$188-$106